JMJD7-PLA2G4B is a read-through fusion transcript that combines the jumonji domain containing 7 (JMJD7) and phospholipase A2, group IVB (PLA2G4B) genes on chromosome 15. In head and neck squamous cell carcinoma (HNSCC), this fusion gene promotes cell proliferation and survival through AKT phosphorylation modulation and regulation of the SKP2 E3 ligase, which controls G1/S phase progression by suppressing p21 and p27 expression 1. JMJD7-PLA2G4B knockdown inhibits HNSCC cell proliferation, induces G1 arrest, and increases starvation-induced cell death 1. Beyond cancer, JMJD7-PLA2G4B is implicated in linoleic acid metabolism dysregulation in metabolic syndrome, where it is significantly downregulated in affected individuals 2. In colorectal cancer, JMJD7-PLA2G4B serves as one of seven prognostic genes in a non-apoptotic regulatory cell death model predicting patient survival and immunotherapy responsiveness 3. Additionally, rare variants in JMJD7-PLA2G4B have been identified as potential genetic risk factors for autism spectrum disorders, with variants observed exclusively in affected individuals and absent from public databases 4. These findings suggest JMJD7-PLA2G4B functions as a multifunctional oncogenic and metabolic regulator with clinical significance in cancer prognosis and neurodevelopmental disease susceptibility.